178 related articles for article (PubMed ID: 10213009)
1. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
Cunningham D; Glimelius B
Semin Oncol; 1999 Feb; 26(1 Suppl 5):6-12. PubMed ID: 10213009
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Van Cutsem E; Blijham GH
Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
[TBL] [Abstract][Full Text] [Related]
3. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Cunningham D; Pyrhönen S; James RD; Punt CJ; Hickish TF; Heikkila R; Johannesen TB; Starkhammar H; Topham CA; Awad L; Jacques C; Herait P
Lancet; 1998 Oct; 352(9138):1413-8. PubMed ID: 9807987
[TBL] [Abstract][Full Text] [Related]
4. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Mitry E; Ducreux M; Rougier P
Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
[TBL] [Abstract][Full Text] [Related]
5. Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
Cunningham D
Semin Oncol; 1999 Feb; 26(1 Suppl 5):1-5. PubMed ID: 10213008
[TBL] [Abstract][Full Text] [Related]
6. Comparing irinotecan with best supportive care and infusional 5-fluorouracil: a critical evaluation of the results of two randomized phase III trials.
Wilke HJ
Semin Oncol; 1999 Feb; 26(1 Suppl 5):21-3. PubMed ID: 10213011
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
Rougier P; Van Cutsem E; Bajetta E; Niederle N; Possinger K; Labianca R; Navarro M; Morant R; Bleiberg H; Wils J; Awad L; Herait P; Jacques C
Lancet; 1998 Oct; 352(9138):1407-12. PubMed ID: 9807986
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan: toward clinical end points in drug development.
Pazdur R
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
[TBL] [Abstract][Full Text] [Related]
9. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
11. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Van Cutsem E; Peeters M
Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
[TBL] [Abstract][Full Text] [Related]
12. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Van Cutsem E; Cunningham D; Ten Bokkel Huinink WW; Punt CJ; Alexopoulos CG; Dirix L; Symann M; Blijham GH; Cholet P; Fillet G; Van Groeningen C; Vannetzel JM; Levi F; Panagos G; Unger C; Wils J; Cote C; Blanc C; Hérait P; Bleiberg H
Eur J Cancer; 1999 Jan; 35(1):54-9. PubMed ID: 10211088
[TBL] [Abstract][Full Text] [Related]
13. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
Gibbs P; Clingan PR; Ganju V; Strickland AH; Wong SS; Tebbutt NC; Underhill CR; Fox RM; Clavant SP; Leung J; Pho M; Brown TJ
Cancer Chemother Pharmacol; 2011 Jan; 67(1):153-63. PubMed ID: 20333384
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan may extend survival in people with metastatic colorectal cancer.
Oncology (Williston Park); 1998 Oct; 12(10):1512. PubMed ID: 9798204
[No Abstract] [Full Text] [Related]
16. The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.
Michael M; Hedley D; Oza A; Feld R; Pintilie M; Goel R; Maroun J; Jolivet J; Fields A; Lee IM; Moore MJ
Clin Colorectal Cancer; 2002 Aug; 2(2):93-101. PubMed ID: 12453323
[TBL] [Abstract][Full Text] [Related]
17. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
Schmitt C; Blijham G; Jolain B; Rougier P; Van Cutsem E
Anticancer Drugs; 1999 Jul; 10(6):617-23. PubMed ID: 10885910
[TBL] [Abstract][Full Text] [Related]
18. [Irinotecan in the second-line therapy of metastatic colorectal carcinoma].
Petrasch S; Dörr T; Kemmeries G
Z Gastroenterol; 1999 Jun; 37(6):575-7. PubMed ID: 10427662
[No Abstract] [Full Text] [Related]
19. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thuss-Patience PC; Kretzschmar A; Bichev D; Deist T; Hinke A; Breithaupt K; Dogan Y; Gebauer B; Schumacher G; Reichardt P
Eur J Cancer; 2011 Oct; 47(15):2306-14. PubMed ID: 21742485
[TBL] [Abstract][Full Text] [Related]
20. The role of irinotecan in colorectal cancer.
Saltz LB
Curr Oncol Rep; 1999; 1(2):155-60. PubMed ID: 11122813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
